cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

May 1, 2022

Study Completion Date

May 1, 2023

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Sintilimab

Sintilimab (200mg ivdrip D1 Q3W)

DEVICE

TACE

TACE will be performed by clinical demand, the interval between two TACEs is not less than 4 weeks.

Trial Locations (1)

Zhongshan Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER